NFL Biosciences SA (ALNFL.PA)
EUR 1.88
(-2.59%)
EUR 1.88
(-2.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.27 Million EUR | -134.55% |
| 2022 | -970.32 Thousand EUR | 67.16% |
| 2021 | -2.95 Million EUR | -1211.97% |
| 2020 | -225.2 Thousand EUR | -0.12% |
| 2019 | -224.93 Thousand EUR | -1027.43% |
| 2018 | -19.95 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.49 Million EUR | -53.47% |
| 2023 Q4 | -2.27 Million EUR | 30.76% |
| 2023 FY | -2.27 Million EUR | -134.55% |
| 2023 Q2 | -3.28 Million EUR | -238.72% |
| 2022 FY | -970.32 Thousand EUR | 67.16% |
| 2022 Q4 | -970.32 Thousand EUR | 50.47% |
| 2022 Q2 | -1.95 Million EUR | 0.0% |
| 2021 FY | -2.95 Million EUR | -1211.97% |
| 2021 Q2 | 113.86 Thousand EUR | 0.0% |
| 2020 FY | -225.2 Thousand EUR | -0.12% |
| 2019 FY | -224.93 Thousand EUR | -1027.43% |
| 2018 FY | -19.95 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -218.749% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 98.842% |
| Adocia SA | 127 Thousand EUR | 1892.024% |
| Aelis Farma SA | -16.19 Million EUR | 85.944% |
| Biophytis S.A. | 2.7 Million EUR | 184.198% |
| Advicenne S.A. | 12.17 Million EUR | 118.693% |
| genOway Société anonyme | 2.97 Million EUR | 176.552% |
| IntegraGen SA | -709.74 Thousand EUR | -220.658% |
| Medesis Pharma S.A. | 1.15 Million EUR | 296.499% |
| Neovacs S.A. | -237.08 Thousand EUR | -859.93% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 152.241% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -174.02% |
| Sensorion SA | 1.37 Million EUR | 265.131% |
| Theranexus Société Anonyme | 2.44 Million EUR | 193.115% |
| TME Pharma N.V. | -1.07 Million EUR | -110.924% |
| Valbiotis SA | -18.13 Million EUR | 87.453% |
| TheraVet SA | 12.78 Thousand EUR | 17901.095% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 204.398% |
| argenx SE | -1.83 Billion EUR | 99.876% |
| BioSenic S.A. | 28.04 Million EUR | 108.115% |
| Celyad Oncology SA | -6.1 Million EUR | 62.703% |
| DBV Technologies S.A. | -114.95 Million USD | 98.02% |
| Galapagos NV | -157.2 Million EUR | 98.552% |
| Genfit S.A. | -7.61 Million EUR | 70.098% |
| GeNeuro SA | 5.91 Million EUR | 138.506% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 90.937% |
| Innate Pharma S.A. | -30.71 Million EUR | 92.59% |
| Inventiva S.A. | 10.48 Million EUR | 121.698% |
| MaaT Pharma SA | -10.2 Million EUR | 77.698% |
| MedinCell S.A. | 39.5 Million EUR | 105.762% |
| Nanobiotix S.A. | -24.71 Million EUR | 90.793% |
| Onward Medical N.V. | -12.89 Million EUR | 82.349% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 259.115% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 108.389% |
| Oxurion NV | 10.71 Million EUR | 121.25% |
| Pharming Group N.V. | 99.4 Million EUR | 102.29% |
| Poxel S.A. | 44.55 Million EUR | 105.108% |
| GenSight Biologics S.A. | 16.29 Million EUR | 113.968% |
| Transgene SA | -14.4 Million EUR | 84.205% |
| Financière de Tubize SA | 78.62 Million EUR | 102.895% |
| UCB SA | 2.17 Billion EUR | 100.105% |
| Valneva SE | 82.73 Million EUR | 102.751% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 87.714% |